Return to home page
Searching: Muskingum library catalog
We are currently experiencing delivery delays for items requested from other institutions while transitioning to a new statewide delivery service. Please contact your library with questions or advice about alternative resources. Thank you for your patience!
  Previous Record Previous Item Next Item Next Record
  Reviews, Summaries, etc...
EBOOK
Title Management of chemotherapy-induced nausea and vomiting : new agents and new uses of current agents / Rudolph M. Navari, editor.
Imprint Cham : Adis/Springer, [2016]

LOCATION CALL # STATUS MESSAGE
 OHIOLINK SPRINGER EBOOKS    ONLINE  
View online
LOCATION CALL # STATUS MESSAGE
 OHIOLINK SPRINGER EBOOKS    ONLINE  
View online
Subject Cancer -- Chemotherapy -- Complications.
Nausea -- Chemotherapy.
Vomiting -- Chemotherapy.
Neoplasms -- drug therapy.
Nausea -- drug therapy.
Vomiting -- drug therapy.
Alt Name Navari, Rudolph M.,
Description 1 online resource
Bibliography Note Includes bibliographical references.
Contents Biography; Contents; Chapter 1: Introduction; References; Chapter 2: The Physiology and Pharmacology of Nausea and Vomiting Induced by Anticancer Chemotherapy in Humans; 2.1 Introduction; 2.2 Why Should Anticancer Therapies Induce Nausea and Vomiting? An Evolutionary Perspective; 2.3 Animal Models vs. the Clinic and the Problems of Studying Nausea in Humans; 2.3.1 Cancer Patients and Animal Models: Limitations; 2.3.2 The Problems of Studying Nausea in Humans; 2.3.2.1 Definition; 2.3.2.2 Biomarkers; 2.3.2.3 Investigating Nausea in Patients and Healthy Volunteers.
2.3.2.4 Assessing Efficacy of Anti-emetics Against Nausea2.3.2.5 Can Nausea Be Studied in Animals?; 2.4 The Physiology of Nausea; 2.4.1 Hormones; 2.4.2 The Autonomic Nervous System and the Stomach; 2.4.3 The Brain; 2.5 The Physiology of Retching and Vomiting; 2.5.1 Pre-expulsion; 2.5.1.1 Skin; 2.5.1.2 Cardiovascular System; 2.5.1.3 Digestive Tract; 2.5.2 Expulsion; 2.5.3 Between Emetic Episodes; 2.6 Inputs: How Are Nausea and Vomiting Induced?; 2.6.1 The Tongue and Pharynx; 2.6.2 The Gastrointestinal Tract and Visceral Afferents; 2.6.2.1 Abdominal Vagal Afferents; Mechanoreceptors.
Mucosal Afferents2.6.2.2 Splanchnic Afferents; 2.6.3 The Area Postrema; 2.6.4 The Vestibular System and Vestibulo-Visual Conflicts; 2.6.5 Cortical Inputs; 2.7 Central Integration; 2.8 Endogenous Anti-emetic Mechanisms; 2.8.1 Pulmonary Vagal Afferents; 2.8.2 Brain Mechanisms; 2.9 Acute and Delayed CINV: Mechanism, Pathways and Aspects of Anti-emetic Pharmacology; 2.9.1 Before Chemotherapy; 2.9.2 Acute Phase of Emesis Induced by Chemotherapy; 2.9.2.1 The Latent Period and the Enterochromaffin Cell-Vagal Afferent Unit; 2.9.2.2 Sustaining and Stopping the Acute Emetic Response.
2.9.3 Delayed Phase Induced by Chemotherapy2.9.3.1 Subsequent Cycles; 2.10 Concluding Comments; References; Chapter 3: First-Generation 5-HT3 Receptor Antagonists; 3.1 Introduction; 3.2 Physiology of CINV; 3.3 Development of First-Generation 5-HT3 Antagonists; 3.3.1 Ondansetron; 3.3.2 Dolasetron; 3.3.3 Tropisetron; 3.3.4 Granisetron; 3.4 Development of Palonosetron; 3.5 Clinical Studies; 3.5.1 Initial Studies; 3.5.1.1 Placebo-Controlled Studies; 3.5.1.2 Dose-Finding Studies; 3.5.1.3 Comparison Studies with Older Agents; 3.5.2 The Role of Corticosteroids.
3.5.3 First-Generation 5-HT3 Antagonists Compared3.5.4 Intravenous Compared to Oral Therapy; 3.5.5 Summary of Characteristics of First-Generation 5-HT3 Receptor Antagonists; 3.6 Palonosetron: A Second-Generation 5-HT3 Antagonist; 3.7 Novel Delivery Methods; 3.7.1 Transdermal Granisetron; 3.7.2 Sustained-Release Subcutaneous Granisetron; 3.8 Conclusion; References; Chapter 4: Palonosetron; 4.1 Development of Palonosetron; 4.2 Safety; 4.3 Clinical Development of Palonosetron; 4.4 Alternative Formulations; 4.5 Multiple-Day Chemotherapy.
Summary This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients' perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.
Note Online resource; title from PDF title page (EBSCO, viewed February 01, 2016).
ISBN 9783319270166 (electronic bk.)
3319270168 (electronic bk.)
3319270141 (print)
9783319270142 (print)
9783319270142
ISBN/ISSN 10.1007/978-3-319-27016-6
OCLC # 936117877
Additional Format Print version: Navari, Rudolph M. Management of Chemotherapy-Induced Nausea and Vomiting : New Agents and New Uses of Current Agents. Cham : Springer International Publishing, 2016 9783319270142



If you experience difficulty accessing or navigating this content, please contact the OPAL Support Team